Search Results
Addition of Targeted Drug Reduces Risk of First-Line Treatment Failure in Advanced Hodgkin Lymphoma
LongTerm Treatment Side Effects
23rd Masterclass Lecture on Hodgkin's Lymphoma - Current Treatment Strategy, Wednesday 31st May
Dr. Kahl on ADCT-402 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Day 2 - Lymphoma Subtypes and Therapies - 1
GESR-CME: Prof. Dr. med. George Mikhaeel (Aggressive non-Hodgkin Lymphoma: radiotheray concepts)
Advancements in Treatment - Dr. Neil Berinstein
Initial Therapy of Advanced Stage Hodgkin Lymphoma: When to Use ABVD, A(BV)VD, and BEACOPP
Dr. Hamlin Discusses Integrating Brentuximab Vedotin
How Hodgkin Lymphoma Treatment is CHANGING: Less Chemo, Targeted Drugs & Longer Survival
Update on Hodgkin Lymphoma | LRF Webinars
Current Challenges in the Treatment of Relapsed/Refractory Malignant Haematological Conditions
